ArticleThe Lancet regional health. Europe2023

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021.

Mariam Elmegaard Malik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.